https://www.selleckchem.com/pr....oducts/citarinostat-
9% [90% confidence interval (CI) 17.0-41.3], which did not meet the primary endpoint. Median overall survival, progression-free survival, and response rates were 7.6 months (95% CI 6.0-10.7), 4.0 months (95% CI 2.0-4.6), and 26.7% (95% CI 14.6-41.9), respectively, in all registered patients. The GEMOX regimen was generally tolerated; the most common grade three or higher adverse events were hematological toxicities. Conclusion GEMOX did not show the expected efficacy in patients with metastatic pancreatic cancer with a fami
Like
Comment
Share
